Hormone replacement therapy - The controversy
DOI:
https://doi.org/10.32385/rpmgf.v19i4.9960Keywords:
Menopause, estrogens, progestogens, Cardiovascular Disease, Osteoporosis, Breast NeoplasiaAbstract
A Hormone Replacement Therapy (HRT) with estrogen alone, or in combination with progestin, was, until recently, a preferred therapeutic in the prevention and treatment of many of the problems of climacteric. He got up, still, the hope of its effects in primary and even secondary cardiovascular disease. Recent studies have, however, lead to a more cautious, the use of these drugs. These suggest an increased risk of cardiovascular and breast cancer in women using HRT. These studies show, however, some limitations as important by many authors. On the other hand, increases the risk encountered, were smaller. Based on current knowledge, therefore continues to recommend itself, a careful evaluation of the risks and benefits of HRT for each woman, a sharing of decisions between doctor and patient and an annual reassessment of the situation. Should not be forgotten the alternatives therapeutic effects are well documented, such as aspirin, statins and control of hypertension, cardiovascular risk reduction, bisphosphonates, and others in the treatment of osteoporosis and other for other health problems climacteric.Downloads
Downloads
Published
Issue
Section
License
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.